Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Seth J. Zost, Pavlo Gilchuk, Rita E. Chen, James Brett Case, Joseph X. Reidy, Andrew Trivette, Rachel S. Nargi, Rachel E. Sutton, Naveenchandra Suryadevara, Elaine C. Chen, Elad Binshtein, Swathi Shrihari, Mario Ostrowski, Helen Y. Chu, Jonathan E. Didier, Keith W. MacRenaris, Taylor Jones, Samuel Day, Luke Myers, F. Eun-Hyung LeeDoan C. Nguyen, Ignacio Sanz, David R. Martinez, Paul W. Rothlauf, Louis Marie Bloyet, Sean P.J. Whelan, Ralph S. Baric, Larissa B. Thackray, Michael S. Diamond, Robert H. Carnahan, James E. Crowe

Research output: Contribution to journalArticlepeer-review

184 Scopus citations

Abstract

Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date1,2. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms.

Original languageEnglish
Pages (from-to)1422-1427
Number of pages6
JournalNature medicine
Volume26
Issue number9
DOIs
StatePublished - Sep 1 2020

Fingerprint

Dive into the research topics of 'Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein'. Together they form a unique fingerprint.

Cite this